Technical Analysis for SDGR - Schrodinger, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical SDGR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 50 DMA Resistance | Bearish | -2.69% | |
| Inside Day | Range Contraction | -2.69% | |
| Wide Bands | Range Expansion | -2.69% | |
| 50 DMA Resistance | Bearish | -3.92% | |
| MACD Bullish Centerline Cross | Bullish | -3.92% | |
| Wide Bands | Range Expansion | -3.92% | |
| NR7 | Range Contraction | -0.36% | |
| Wide Bands | Range Expansion | -0.36% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 10 DMA Support | about 14 hours ago | |
| Down 3% | about 17 hours ago | |
| Down 2 % | about 17 hours ago | |
| Fell Below Previous Day's Low | about 17 hours ago | |
| 60 Minute Opening Range Breakdown | about 17 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/10/2020
- Sector: Healthcare
- Industry: Health Information Services
Schrödinger, Inc. provides chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. Schrödinger was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in August 1990 and is headquartered in New York, NY.
Pharmaceutical Industry Drug Discovery Simulation Pre Clinical Development
Pharmaceutical Industry Drug Discovery Simulation Pre Clinical Development
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 99.5 |
| 52 Week Low | 25.5 |
| Average Volume | 1,529,507 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 57.80 |
| 20-Day Moving Average | 53.54 |
| 10-Day Moving Average | 56.90 |
| Average True Range | 3.35 |
| ADX | 19.14 |
| +DI | 25.34 |
| -DI | 17.96 |
| Chandelier Exit (Long, 3 ATRs ) | 52.22 |
| Chandelier Exit (Short, 3 ATRs ) | 56.31 |
| Upper Bollinger Band | 61.91 |
| Lower Bollinger Band | 45.16 |
| Percent B (%b) | 0.63 |
| BandWidth | 31.29 |
| MACD Line | 0.18 |
| MACD Signal Line | -0.57 |
| MACD Histogram | 0.7487 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 59.35 | ||||
| Resistance 3 (R3) | 59.68 | 58.79 | 58.73 | ||
| Resistance 2 (R2) | 58.79 | 57.85 | 58.62 | 58.53 | |
| Resistance 1 (R1) | 57.23 | 57.28 | 56.79 | 56.90 | 58.32 |
| Pivot Point | 56.34 | 56.34 | 56.12 | 56.17 | 56.34 |
| Support 1 (S1) | 54.78 | 55.40 | 54.34 | 54.45 | 53.02 |
| Support 2 (S2) | 53.89 | 54.83 | 53.72 | 52.81 | |
| Support 3 (S3) | 52.33 | 53.89 | 52.61 | ||
| Support 4 (S4) | 52.00 |
